Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Mylan, Herbalife and T-Mobile are making headlines this Monday morning.
The pharmaceutical company will offer patients a two-pack carton at half price of the branded version.
Dr. Josh Sharfstein, Johns Hopkins University and Former FDA official, discusses the role of the FDA in drug pricing and competition in the pharmaceutical space.
CNBC's Meg Tirrell reports on the fears in the biotech market following the Mylan EpiPen pricing saga, as well as the news that Mylan will launch a generic EpiPen auto-injector.
EpiPen maker Mylan announcing it will launch a generic epinephrine auto-injector with a list price of $300 for a two pack. The "Squawk Box" crew discusses the news.
Linette Lopez, Business Insider Senior Finance Editor, explains how further price hikes on the EpiPen could make a lot of money for Mylan CEO Heather Bresch. CNBC's Meg Tirrell weighs in.
David Martin, M-CAM Founder, discusses the EpiPen pricing saga and his view that the patent office gave Mylan an unjustified monopoly on the drug.
Amid the Mylan EpiPen pricing saga, should there be greater regulation on the pharmaceuticals industry? Former Vermont Governor Howard Dean and CNBC Senior Contributor Larry Kudlow debate the issue.
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.
CNBC contributor Mike Khouw dives into the options for Express Scripts amid the EpiPen pricing controversy.
Rep. Lloyd Doggett (D-Texas) discusses the EpiPen pricing saga and his views on greater price gouging in the drug industry with the "Fast Money" traders.
Amid the Mylan EpiPen pricing saga, CNBC's Meg Tirrell looks at the drugs that may be next in line for controversial price hikes.
Sen. Amy Klobuchar (D-Minn.) discusses the call for the FTC to investigate Mylan and other "bad actors" over drug pricing rules.
Sen. Amy Klobuchar (D-Minn.) discusses legislation for EpiPen-like generic drugs to be more widely available, pricing controls and drug importation from Canada.
Sen. Amy Klobuchar (D-Minn.) discusses Mylan CEO Heather Bresch's comments on the EpiPen pricing controversy.
Steve Miller, Express Scripts chief medical officer, responds to Mylan's CEO Heather Bresch blaming the "middle men" for higher drug prices.
To blame the healthcare system is what Mylan CEO Heather Bresch told CNBC today in explaining why the price of her company's EpiPen has seen price hikes of 400%. CNBC's Meg Tirrell breaks down the pharma supply chain system.
CNBC's Meg Tirrell reports on the Pharmaceutical Care Management Association's response to Mylan blaming "the middlemen" for its EpiPen price hike.
Sen. Charles Grassley (R-Iowa), shares his take on Congress, drug price control and the prohibition on importing drugs.